European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV.
about
Association of HIV and ART with cardiometabolic traits in sub-Saharan Africa: a systematic review and meta-analysisEffects of Pitavastatin on Lipid Profiles in HIV-Infected Patients with Dyslipidemia and Receiving Atazanavir/Ritonavir: A Randomized, Double-Blind, Crossover StudyPredicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study.Presence of the metabolic syndrome is not a better predictor of cardiovascular disease than the sum of its components in HIV-infected individuals: data collection on adverse events of anti-HIV drugs (D:A:D) study.Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study.Protein adducts as prospective biomarkers of nevirapine toxicity.Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV.Statin drug interactions and related adverse reactions.The effects of dietary intervention on HIV dyslipidaemia: a systematic review and meta-analysisUnderstanding diabetes in patients with HIV/AIDSAnalysis of suppressor and non-suppressor FOXP3+ T cells in HIV-1-infected patients.Monitoring HIV-infected Patients with Diabetes: Hemoglobin A1c, Fructosamine, or Glucose?Cost of surgical intervention for reconstructive therapy of HIV-associated facial lipoatrophy.Bone disease in HIV infection: a practical review and recommendations for HIV care providers.Hypertension, cardiovascular risk factors and antihypertensive medication utilisation among HIV-infected individuals in Rakai, Uganda.Comparative Effectiveness and Toxicity of Statins Among HIV-Infected PatientsStimulating high impact HIV-related cardiovascular research: recommendations from a multidisciplinary NHLBI Working Group on HIV-related heart, lung, and blood disease.Lipodystrophy: pathophysiology and advances in treatmentSouth Asian Consensus Guidelines for the rational management of diabetes in human immunodeficiency virus/acquired immunodeficiency syndrome.Recommendations for evaluation and management of bone disease in HIV.New and emerging agents in the management of lipodystrophy in HIV-infected patients.Management of dyslipidemia in HIV-infected patients.Insulin resistance by homeostasis model assessment in HIV-infected patients on highly active antiretroviral therapy: cross-sectional study.Glycated Hemoglobin A(1c) as screening for diabetes mellitus in HIV-infected individualsRole of the Pharmacist in Caring for Patients with HIV/AIDS: Clinical Practice Guidelines.Dysregulation of glucose metabolism in HIV patients: epidemiology, mechanisms, and management.Randomised controlled pilot study to assess the feasibility of a Mediterranean Portfolio dietary intervention for cardiovascular risk reduction in HIV dyslipidaemia: a study protocol.Approach to the human immunodeficiency virus-infected patient with lipodystrophyAnkle-brachial index in HIV infection.HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options.Mind the gap: difference between Framingham heart age and real age increases with age in HIV-positive individuals-a clinical cohort studyDyslipidemia and cardiovascular risk in human immunodeficiency virus infection.A1C underestimates glycemia in HIV infectionLipid management in patients who have HIV and are receiving HIV therapy.Serious Non-AIDS events: Immunopathogenesis and interventional strategies.Immune deficiency could be an early risk factor for altered insulin sensitivity in antiretroviral-naive HIV-1-infected patients: the ANRS COPANA cohort.Determinants of developing widened spatial QRS-T angle in HIV-infected individuals: results from the Strategies for Management of Antiretroviral Therapy [SMART] Study.Bone mineral density effects of randomized regimen and nucleoside reverse transcriptase inhibitor selection from ACTG A5142.Thirty years of the human immunodeficiency virus epidemic and beyond.Metabolic complications associated with antiretroviral therapy in HIV-infected and HIV-exposed uninfected paediatric patients.
P2860
Q27000959-B8FE44DE-C20D-4F6B-9585-8FB9EA8DBF86Q28550267-E79E91BF-45EE-427D-829E-C071369437C1Q30573969-F6BD8994-C62C-4858-8C09-A9FA7C450D7DQ33389734-83BBEC95-C23E-4C3D-9FAC-FF433E0BC7D5Q33602915-8E1C9637-AD3E-4C96-B68B-D02D996509AFQ33681307-AD475346-650D-4435-84A1-550A2D3EBC0BQ33962303-F7224E4B-3436-4BA1-8420-076A7C3ED0DDQ34292468-9613EB9B-4CF6-4B58-9876-3711D7EA78F5Q34305333-8E385468-F63C-478F-B411-32771C7B5E85Q34515251-C6063D7B-04C7-4C4F-83A5-73D6F126E4B3Q34534197-D46B9DF5-2786-411F-9E46-22C17AB4DEC9Q34655515-87CD3D31-41B6-41B5-B546-C39857244B1BQ35018992-E9AFD3AD-6F93-4618-A703-8C47E7A788F8Q35019051-86554BA4-249E-4301-ADAA-7BDB7DC2117AQ35019636-A546A715-56BD-43D3-A13F-FB48F2366238Q35019859-28588F02-DCE4-4BEF-B4C7-F04C6F021A37Q35089263-33B94E06-953B-4AD7-BEB1-48FD6ECA331CQ35148915-BA874D33-E2A7-4794-AE5A-8D693EEA8E44Q35352433-2A232EA8-86BC-4F94-A572-70E228D78FE0Q35451868-309FF920-2BC0-466F-992E-A39CBC55022FQ35557229-1E0472D7-D935-423E-9BFE-3C6D2DE8FB4DQ35643573-1F1D9766-037F-495D-9C5A-EAE8006AB6D3Q35670873-B4042504-E8AA-4DB4-8F66-8B3F47FAFAAAQ35865324-5B91465A-2480-4969-9F0B-AD159BB60623Q35898538-E876E5B9-58B3-42F7-9318-513D48E109F8Q36158019-C795DF80-5894-43F2-82D4-5A6F292BDF39Q36559494-EEE57875-8023-44AC-8A08-2DD8D968784DQ36834945-E74CC9A9-3A47-4F29-A7FF-A8A013FC2CA5Q37184316-306643B2-346E-4389-B811-D4BB8B91FA44Q37195539-A6BE2E52-1D09-45C0-B609-846CA9A0E7D2Q37256483-EEC25C48-A7E9-4C66-AF12-5AF1ACB4808AQ37319195-0B0C6578-0D34-4AC2-8AC2-1021C3C4B958Q37319242-3EE3FDB6-1B60-415E-A86A-29783E4CE584Q37366345-D02492F3-5BE0-460D-92FB-9D007F607111Q37418140-4B4A7785-31E4-41D7-A684-93F94AC5AB0BQ37485986-FE4A4093-F661-40B7-82B7-7A74DE1C5B3FQ37633386-C0EA5EB1-AF8B-4B85-8EF7-EEE7D595BD62Q37641866-5C31D04C-CB43-4F2A-BC4D-3F08191FC5A9Q37667360-854E9455-059F-47DD-9E75-9484D9AD440AQ37676229-8CBF3DAA-D394-4C52-BD0F-CD9DBDD4F18C
P2860
European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
European AIDS Clinical Society ...... of metabolic diseases in HIV.
@en
type
label
European AIDS Clinical Society ...... of metabolic diseases in HIV.
@en
prefLabel
European AIDS Clinical Society ...... of metabolic diseases in HIV.
@en
P2093
P2860
P1433
P1476
European AIDS Clinical Society ...... of metabolic diseases in HIV.
@en
P2093
E Martinez
EACS Executive Committee
J D Lundgren
M Battegay
P2860
P356
10.1111/J.1468-1293.2007.00534.X
P577
2008-02-01T00:00:00Z